aTyr Pharma, Inc. (Nasdaq: LIFE) has begun an exciting new public offering of its common stock, giving investors the opportunity to be part of a biotherapeutics company pushing the boundaries of discovery and development of first-in-class medicines. In addition, the underwriters have been granted a 30-day option to purchase up to 15% more of the shares sold in the offering. With the offering subject to market and other conditions, this could be the perfect time to invest in aTyr and its innovative tRNA synthetase platform.
RBC Capital Markets is taking the lead in the offering, acting as sole book-running manager. H.C. Wainwright & Co. is also participating, lending their expertise as the lead manager for the offering.
aTyr Pharma is pleased to announce its recent clearance of an Investigational New Drug (IND) application by the U.S. Food and Drug Administration, granting the company permission to use the net proceeds from the offering to fund the ongoing development of efzofitimod and launch a planned Phase 2 study of the drug in patients with systemic sclerosis (SSc, or scleroderma)-associated interstitial lung disease (SSc-ILD). The remaining funds will be used for working capital, enabling aTyr to continue advancing its research and development and create innovative therapeutics that address unmet medical needs.
Don’t miss out on this incredible opportunity! We are offering an exciting chance to invest in our company and take advantage of our potential growth. Take the first step towards investing in our future and take advantage of this offer before it’s too late. This offer is not available in all states, so check your local laws and regulations to ensure you are eligible.
aTyr is a biotherapeutics company on the cutting edge of discovery, using its proprietary tRNA synthetase platform to develop first-in-class medicines. By exploring an uncharted area of biology – the extracellular functionality and signaling pathways of tRNA synthetases – aTyr has uncovered a potential pipeline of protein compositions derived from 20 tRNA synthetase genes. As its primary focus, aTyr is exploring efzofitimod, a clinical-stage product candidate designed to target the neuropilin-2 receptor and downregulate immune engagement in fibrotic lung disease.